SpyGlass Pharma, Inc.
- SGP · Nasdaq
- Surgical & Medical Instruments & Apparatus
- Irvine, CA
- 65 employees
- CIK 0001778922
Updated from SEC filings through
Top things to know
Executives
- Jean-Frédéric Viret, Ph.D. Chief Financial Officer 10-K, March 26, 2026
- James Dennewill Chief Operating Officer 10-K, March 26, 2026
- Chetan Pujara, Ph.D. Chief Research and Development Officer 10-K, March 26, 2026
SpyGlass Pharma, Inc. is a U.S. public company in surgical & medical instruments & apparatus (SIC 3841), headquartered in Irvine, CA. It trades as SGP on Nasdaq. It reported about 65 employees.
Five-year financials
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | Not on file | Not on file |
| Operating income | -$41.4M 10-K, 2026-03-26 | -$27.1M 10-K, 2026-03-26 |
| SG&A | $12.3M 10-K, 2026-03-26 | $7.1M 10-K, 2026-03-26 |
| Net income | -$39.9M 10-K, 2026-03-26 | -$29.2M 10-K, 2026-03-26 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Jean-Frédéric Viret, Ph.D. | Chief Financial Officer | 10-K, March 26, 2026 |
| James Dennewill | Chief Operating Officer | 10-K, March 26, 2026 |
| Chetan Pujara, Ph.D. | Chief Research and Development Officer | 10-K, March 26, 2026 |
| Ali Behbahani, M.D. | Director | 10-K, March 26, 2026 |
| Habib J. Dable | Director | 10-K, March 26, 2026 |
| Malik Y. Kahook, M.D. | Director | 10-K, March 26, 2026 |
| Patrick Mooney | Director | 10-K, March 26, 2026 |
What SpyGlass Pharma, Inc. does
SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The Company’s mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation.
Press release "About" paragraph, 10-K for the year ending October 19, 2026
Shares and governance
| Shares outstanding | 33.5 million (as of November 2, 2026) | 10-Q, November 12, 2026 |
|---|---|---|
| Public float | $0 (as of June 30, 2025) | 10-K, March 26, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 12, 2026 |
| Auditor | Deloitte & Touche LLP (Costa Mesa, CA) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 16, 2026 | Capital Nexus Fund L.P. RA III Director | Buy | 1,000 | $32K | Form 4, November 18, 2026 |
| November 16, 2026 | Capital Management L.P. Ra Director | Buy | 1,000 | $32K | Form 4, November 18, 2026 |
| November 16, 2026 | Peter Kolchinsky Director | Buy | 1,000 | $32K | Form 4, November 18, 2026 |
| November 16, 2026 | Capital Healthcare Fund LP RA Director | Buy | 1,000 | $32K | Form 4, November 18, 2026 |
| November 16, 2026 | Rajeev M. Shah Director | Buy | 1,000 | $32K | Form 4, November 18, 2026 |
| February 9, 2026 | Bilal Arshad Khan Director | Buy | 135,000 | $2.2M | Form 4, February 11, 2026 |
| February 9, 2026 | Geoffrey B. Pardo Director | Buy | 312,500 | $5.0M | Form 4, February 11, 2026 |
| February 9, 2026 | Peter Kolchinsky Director | Buy | 3,690,000 | $59.0M | Form 4, February 11, 2026 |
Recent 8-K events
- 8-K filed 2026-11-12
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 8.01 Other events
- 8-K filed 2026-10-19
- Item 8.01 Other events
- 8-K filed 2026-10-01
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-08-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-14
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-26
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-09
- Item 8.01 Other events
- 8-K filed 2026-02-13
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-02-09
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- Item 7.01 Regulation FD disclosure
Frequently asked questions about SpyGlass Pharma, Inc.
- What does SpyGlass Pharma, Inc. do?
- In its own words, from Item 1 of its 10-K: "SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The Company’s mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation."
- How many employees does SpyGlass Pharma, Inc. have?
- About 65 as of December 31, 2025, as stated in its annual report.
- Who is the CFO of SpyGlass Pharma, Inc.?
- Jean-Frédéric Viret, Ph.D., Chief Financial Officer, as named in a 10-K filed March 26, 2026.
- Where is SpyGlass Pharma, Inc. headquartered?
- Irvine, CA.
- What is SpyGlass Pharma, Inc.'s stock ticker?
- SGP on Nasdaq.
- What industry is SpyGlass Pharma, Inc. in?
- Surgical & Medical Instruments & Apparatus, SIC code 3841.
- What is SpyGlass Pharma, Inc.'s website?
- spyglasspharma.com. Investor relations: https://ir.spyglasspharma.com/.
- When does SpyGlass Pharma, Inc. report earnings next?
- February 4, 2027. This is an estimate from past filing dates, not a confirmed date.
- Is SpyGlass Pharma, Inc. a public company?
- Yes. SpyGlass Pharma, Inc. files with the SEC under CIK 0001778922 and trades as SGP.
- Who audits SpyGlass Pharma, Inc.?
- Deloitte & Touche LLP, Costa Mesa, CA, as named in its latest annual report (10-K).
- How many shares of SpyGlass Pharma, Inc. are outstanding?
- 33.5 million shares as of November 2, 2026, from its 10-Q filed November 12, 2026.
- What is SpyGlass Pharma, Inc.'s public float?
- $0 as of June 30, 2025, as reported on the cover of its 10-K filed March 26, 2026.
- How many business segments does SpyGlass Pharma, Inc. report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 12, 2026.
- Have SpyGlass Pharma, Inc. insiders traded stock recently?
- Since February 9, 2026, officers and directors reported 0 open-market sales and 14 purchases worth about $320M on Forms 4 and 5. The most recent: Capital Nexus Fund L.P. RA III (Director) bought 1,000 shares on November 16, 2026.